Natixis Advisors LLC Acquires 1,491 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)

Natixis Advisors LLC increased its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 11.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,581 shares of the company’s stock after purchasing an additional 1,491 shares during the period. Natixis Advisors LLC’s holdings in Prestige Consumer Healthcare were worth $1,051,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Opal Wealth Advisors LLC bought a new stake in shares of Prestige Consumer Healthcare during the 2nd quarter worth about $26,000. Quest Partners LLC lifted its holdings in Prestige Consumer Healthcare by 2,826.7% in the 2nd quarter. Quest Partners LLC now owns 439 shares of the company’s stock worth $30,000 after purchasing an additional 424 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in Prestige Consumer Healthcare by 80.6% during the first quarter. EverSource Wealth Advisors LLC now owns 466 shares of the company’s stock worth $33,000 after purchasing an additional 208 shares during the period. Northwestern Mutual Wealth Management Co. grew its holdings in Prestige Consumer Healthcare by 562.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock valued at $35,000 after purchasing an additional 433 shares during the last quarter. Finally, Gladius Capital Management LP bought a new position in shares of Prestige Consumer Healthcare in the second quarter valued at approximately $35,000. 99.95% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Jefferies Financial Group reiterated a “hold” rating and issued a $76.00 target price (up from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. DA Davidson reaffirmed a “buy” rating and issued a $95.00 price target on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. One equities research analyst has rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $83.67.

Prestige Consumer Healthcare Trading Down 1.7 %

Shares of Prestige Consumer Healthcare stock opened at $83.18 on Wednesday. The company has a market cap of $4.11 billion, a price-to-earnings ratio of 20.24, a PEG ratio of 2.39 and a beta of 0.47. Prestige Consumer Healthcare Inc. has a 1 year low of $56.61 and a 1 year high of $86.36. The company’s fifty day simple moving average is $74.76 and its 200-day simple moving average is $70.88. The company has a current ratio of 3.56, a quick ratio of 2.10 and a debt-to-equity ratio of 0.61.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.09. The company had revenue of $283.79 million for the quarter, compared to analyst estimates of $282.09 million. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The business’s quarterly revenue was down .9% on a year-over-year basis. During the same period last year, the business posted $1.07 EPS. As a group, sell-side analysts expect that Prestige Consumer Healthcare Inc. will post 4.45 EPS for the current year.

Insider Activity at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, EVP Adel Mekhail sold 9,063 shares of Prestige Consumer Healthcare stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $82.00, for a total transaction of $743,166.00. Following the sale, the executive vice president now owns 18,365 shares in the company, valued at $1,505,930. The trade was a 33.04 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Mary Beth Fritz sold 9,885 shares of the business’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $81.97, for a total transaction of $810,273.45. Following the completion of the sale, the senior vice president now directly owns 18,835 shares in the company, valued at $1,543,904.95. This trade represents a 34.42 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 38,810 shares of company stock worth $3,187,300 over the last three months. Company insiders own 1.60% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.